This SARS-CoV-2 Nucleocapsid antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Purification
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody is affinity chromatography purified via peptide column.
Immunogen
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody was raised against a peptide corresponding to 17 amino acids near the center of SARS-CoV-2 (COVID-19) Nucleocapsid protein. The immunogen is located within 230-280 amino acids of SARS-CoV-2 (COVID-19) Nucleocapsid protein.
SARS-CoV-2 N
Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)
ELISA, IF
Host: Human
Monoclonal
CR3018 (03-018)
unconjugated
Recombinant Antibody
Application Notes
WB: 0.5-2 μ,g/mL
SARS-CoV-2 (COVID-19) Nucleocapsid antibody can be used for the detection of SARS-CoV-2 (COVID-19) Nucleocapsid protein in ELISA. It will detect 4 ng of free peptide at 1 μ,g/mL. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
SARS-CoV-2 (COVID-19) Nucleocapsid antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Ren, Irudayaraj: "Paper-Based Test for Rapid On-Site Screening of SARS-CoV-2 in Clinical Samples." in: Biosensors, Vol. 11, Issue 12, (2022) (PubMed).
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).